GiovannoniG. Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy–YES. Mult Scler2016; 22: 1397–1400.
2.
NaismithRT. Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy–NO. Mult Scler2016; 22: 1400–1402.
3.
FeiulletLReuterFAudoinB. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler2007; 13: 124–127.
4.
SchulzDKoppBKunkelA. Cognition in the early stage of multiple sclerosis. J Neurol2006; 253: 1002–1010.
5.
De StefanoNNarayananSFrancisGS. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol2001; 58: 65–70.
6.
HauserSLComiGCHartungH-P. Efficacy and safety of ocrelizumab in relapsing multiple sclerosis—Results of the interferon-beta-1a-controlled, double-blind, phase III OPERA I and II studies. Mult Scler2015; 21(11 Suppl.): 69.
7.
CohenJAColesAJArnoldDL. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomized controlled phase 3 trial. Lancet2012; 380: 1819–1828.
8.
ColesAJTwymanCLArnoldDL. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomized controlled phase 3 trial. Lancet2012; 380: 1828–1839.
9.
GiovannoniGComiGCookS. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med2010; 362: 416–426.
10.
BurtRKBalabanovRHanX. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA2015; 313: 275–284.
11.
NashRAHuttonGJRackeMK. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT–MS): A 3-year interim report. JAMA Neurol2015; 27: 159–169.
12.
MancardiGLSormaniMPGualandiF. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial. Neurology2015; 84: 981–988.
13.
LublinFDCofieldSSCutterGR. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol2013; 73: 327–340.
